BRIEF published on 11/26/2025 at 00:51, 3 months 27 days ago CureVac annonce les résultats de son assemblée générale extraordinaire Assemblée Générale Extraordinaire BioNTech Approbation Des Actionnaires CureVac Fusion Légale
BRIEF published on 11/26/2025 at 00:51, 3 months 27 days ago CureVac Announces Results of Extraordinary General Meeting BioNTech Extraordinary General Meeting CureVac Shareholders Approval Legal Merger
PRESS RELEASE published on 11/26/2025 at 00:46, 3 months 27 days ago CureVac Announces Voting Results of Extraordinary General Meeting CureVac announces approval of BioNTech's exchange offer for outstanding shares at Extraordinary General Meeting with over 99.16% approval rate BioNTech MRNA Technology Exchange Offer CureVac EGM Voting Results
BRIEF published on 11/24/2025 at 13:15, 3 months 28 days ago CureVac publie ses résultats financiers du troisième trimestre et des neuf premiers mois de 2025 Performance Financière CureVac Technologie De L'ARNm Résultats Du Troisième Trimestre 2025 Fusion BioNTech
BRIEF published on 11/24/2025 at 13:15, 3 months 28 days ago CureVac Reports Q3 and Nine-Month Financial Results for 2025 Financial Performance MRNA Technology CureVac Q3 2025 Results BioNTech Merger
PRESS RELEASE published on 11/24/2025 at 13:10, 3 months 28 days ago CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates CureVac announces financial results for Q3 and first nine months of 2025, BioNTech transaction progresses, EMA clearance received for cancer therapy CVHNLC sqNSCLC Financial Results Cancer Therapy CureVac BioNTech Transaction EMA Clearance
BRIEF published on 08/15/2025 at 13:32, 7 months 7 days ago CureVac Reports Q2 and H1 2025 Financial Results; Announces Key Developments Financial Results MRNA Technology CureVac Patent Resolution BioNTech Acquisition
BRIEF published on 08/15/2025 at 13:32, 7 months 7 days ago CureVac publie ses résultats financiers du deuxième trimestre et du premier semestre 2025 et annonce des développements clés Résultats Financiers CureVac Technologie De L'ARNm Résolution De Brevet Acquisition De BioNTech
PRESS RELEASE published on 08/15/2025 at 13:27, 7 months 7 days ago CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates CureVac announces Q2 2025 financial results, business updates & agreement with BioNTech for transformative mRNA treatments. Strong cash position Financial Results BioNTech CureVac MRNA Q2 2025
BRIEF published on 08/08/2025 at 02:20, 7 months 15 days ago CureVac Settles Patent Dispute with Pfizer/BioNTech MRNA Technology CureVac Pfizer/BioNTech Patent Resolution Vaccine Royalties
Published on 03/23/2026 at 02:00, 2 hours 30 minutes ago FutureGen Industries Announces Open Market Investments
Published on 03/20/2026 at 13:30, 2 days 15 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/23/2026 at 03:35, 55 minutes ago Deye 2026 Frankfurt Distributor & Partner Summit Concludes Successfully
Published on 03/22/2026 at 12:23, 16 hours 7 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 2 days 5 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 2 days 7 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 19:00, 2 days 9 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 9 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 10 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 10 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
